Analytical Data
-
Gene name
CDC25B
- Application
-
Alternative Names
CDC25HU2; M-phase inducer phosphatase 2; Dual specificity phosphatase Cdc25B
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30305
-
Expression Region
Glu377~Gln566
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDC25B is a member of the CDC25 phosphatase family, which plays a crucial role in the regulation of the cell cycle by activating cyclin-dependent kinases (CDKs). The enzyme functions primarily by dephosphorylating CDKs, thus promoting the transition from G2 phase to mitosis. Aberrant expression or activity of CDC25B has been implicated in various cancers, making it an important target for cancer research. Studies have shown that CDC25B is overexpressed in several tumor types, contributing to uncontrolled cell proliferation and tumor progression. The recombinant production of CDC25B protein has become a significant focus to understand its biochemical properties, regulatory mechanisms, and interactions with other cell cycle regulators. Such recombinant proteins can be utilized for structural studies, enzyme assays, and the development of small-molecule inhibitors targeting CDC25B. Additionally, understanding the mechanism of CDC25B not only aids in elucidating its role in cancer biology but also assists in the identification of potential therapeutic strategies for malignancies associated with its dysregulation. Overall, the exploration of CDC25B as a recombinant protein serves as a foundational step toward leveraging its biological significance in cancer treatment and cell cycle regulation studies.
